Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.
加利福尼亚州圣马特奥，2024年11月26日（环球新闻社）-- Sagimet生物科学公司（Sagimet，纳斯达克：SGMT），一家处于临床阶段的生物制药公司，致力于开发针对代谢和纤维化通路功能异常的新型治疗药物，今天宣布管理层将于2024年12月3日星期二美国东部时间上午10点在纽约市的派杰投资第36届医疗保健年会上发言。
A webcast of the presentation will be available in the Investors & Media section of Sagimet's website at , with an archived replay available for 90 days following the live event.
演示的网络广播将在Sagimet网站的投资者与媒体栏目中提供，现场活动结束后的90天内可提供存档回放。
About Sagimet Biosciences
关于世纪医药公司
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit .
Sagimet是一家临床阶段的生物制药公司，正在开发新型脂肪酸合成酶（FASN）抑制剂，旨在针对由多余合成脂肪酸棕榈酸所致的疾病中的代谢和纤维化通路。Sagimet的首席候选药物Denifanstat是一种口服、每日一次的药丸，是一种选择性FASN抑制剂，用于治疗与代谢紊乱相关的类脂肪肝（MASH）。基于肝活检的主要终点的FASCINATE-2，Denifanstat在MASH中进行的第20亿期临床试验以积极结果成功完成。Denifanstat已获得FDA授予突破性疗法指定，用于治疗具有中度到重度肝纤维化（与F2至F3纤维化阶段一致）的非肝硬化MASH，与FDA的第2阶段最终阶段互动已经成功完成，支持Denifanstat进入MASH的第3期发展。有关Sagimet的更多信息，请访问。
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
联系方式：
Joyce Allaire
生命科学顾问
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
来源：Sagimet生命科学公司。
译文内容由第三方软件翻译。
